Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly
Agreement provides Lilly, a leader in the development of important cancer therapeutics, with access to ImmunoGen's TAP technology ImmunoGen to receive $20 million upfront, milestone payments potentially totaling $200 million — for each target — and royalties on any commercial sales WALTHAM, Mass.,
View HTML